DNA’s results may be too good for the company’s own good: the 2Q07 operating-profit margin was 42% (!) Numbers like that will strengthen the hand of GPhA in Congressional lobbying for biogenerics legislation.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”